Who makes Livmarli Oral Product?

Livmarli Oral Product is developed by Mirum Pharmaceuticals, Inc..

What development phase is Livmarli Oral Product in?

Livmarli Oral Product is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

Livmarli Oral Product

Mirum Pharmaceuticals, Inc. · FDA-approved active Small molecule Quality 0/100

Livmarli, an oral product developed by Mirum Pharmaceuticals, is currently on the market with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which addresses a significant unmet need in its primary indication. The primary risk to Livmarli is the lack of clear revenue data, which may impact investor confidence and market valuation.

At a glance

Generic name	Livmarli Oral Product
Also known as	Maralixibat
Sponsor	Mirum Pharmaceuticals, Inc.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Livmarli Oral Product CI brief — competitive landscape report
Livmarli Oral Product updates RSS · CI watch RSS
Mirum Pharmaceuticals, Inc. portfolio CI